Vorapaxar: FDA Panel Backs Blood Clot-Preventing Drug For Heart Attack Survivors
The panel voted 10-1 in favor of the drug, which would, if approved, be sold under the brand name Zontivity. The FDA is not
vorapaxar fda panel back blood clot preventing drug heart attack survivor panel vote favor drug approve sell brand zontivity fda